Ado-Trastuzumab Emtansine (Trastuzumab-Dm1) For Treatment Of Her2-Positive Malignancies

Ado-trastuzumab emtansine, also known as trastuzumab-DM1 (T-DM1), is an antibody-drug conjugate that links the human epidermal growth factor receptor 2 (HER2) antagonist activity of trastuzumab to the cytotoxic activity of emtansine (DM1). The HER2 antagonist is intended as a treatment for patients with HER2-overexpressing breast cancers, and it may have applications for other HER2-positive malignancies.